Stock comparison
AstraZeneca
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AZN
AstraZeneca
Market cap
$290.06B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AZN | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 75B | IDXX |
| Benjamin Graham | 73B | 80A | IDXX |
| Philip Fisher | 64C | 75B | IDXX |
| Peter Lynch | 63C | 71B | IDXX |
| Joel Greenblatt | 51C | 83C | IDXX |
| Charlie Munger | 62C | 87A | IDXX |
| Terry Smith | 60D | 84A | IDXX |
Side-by-side metrics
| Metric | AZN | IDXX |
|---|---|---|
| Market cap | $290.06B | $44.12B |
| P/E (TTM) | 27.6x | 39.0x |
| EV/EBIT | 23.0x | 31.6x |
| ROIC (TTM) | 12.88% | 40.66% |
| Gross margin | 79.71% | 62.05% |
| Net margin | 17.19% | 24.63% |
| Revenue CAGR 5y | 11.93% | 7.56% |
| EPS CAGR 5y | 2.01% | 10.79% |
| Debt / Equity | 0.7x | 0.7x |
| Dividend yield | 1.7% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AZN leads on
- Dividend yield1.7%vs 0.0%+100%
- EPS CAGR 5y2.01%vs 10.79%+95%
- Market cap$290.06Bvs $44.12B+85%
- Revenue CAGR 5y11.93%vs 7.56%+37%
IDXX leads on
- ROIC (TTM)40.66%vs 12.88%+68%
- Net margin24.63%vs 17.19%+30%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.